The Expert Council of the Industrial Development Fund (IDF) has approved a loan for organizing the manufacturing of hepatitis A vaccine in Novosibirsk. The cost of the project is 219 million rubles, including a 60 million ruble loan provided by IDF.
The loan will allow JSC Vector-BiAlgam to launch the manufacturing of hepatitis A vaccine in ampoules and syringe doses (finished dosage forms for use in medical practice and for prevention) on its own premises in Novosibirsk.
The site will receive certification for its GMP compliance, as the newly assembled “clean premises” will be connected to the necessary utility systems and and appropriately equipped. This will allow to ensure filling and packaging in full compliance with the requirements of this international standard for the quality of injection medicines, which will enable the manufacturing of competitive Russian-made drugs in order to enter the international pharmaceutical markets. The enterprise plans to export 15% of its products.